Tham khảo Remogliflozin etabonate

↑ Statement on a nonproprietory name adopted by the USAN council
↑ “Avolynt Announces Completion of Phase 2b BRID Study of SGLT2 Inhibitor Remogliflozin-Etabonate” (Thông cáo báo chí). Avolynt, Inc. Truy cập ngày 24 tháng 7 năm 2018.
↑ Mudaliar, S; Armstrong, DA; Mavian, AA; O'Connor-Semmes, R; Mydlow, PK; Ye, J; Hussey, EK; Nunez, DJ; Henry, RR (tháng 11 năm 2012). “Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes”. Diabetes Care. 35 (11): 2198–200. doi:10.2337/dc12-0508. PMC 3476920. PMID 23011728.
↑ Dobbins, RL; O'Connor-Semmes, R; Kapur, A; Kapitza, C; Golor, G; Mikoshiba, I; Tao, W; Hussey, EK (tháng 1 năm 2012). “Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients”. Diabetes Obes Metab. 14 (1): 15–22. doi:10.1111/j.1463-1326.2011.01462.x. PMID 21733056.
↑ Sykes, AP; O'Connor-Semmes, R; Dobbins, R; Dorey, DJ; Lorimer, JD; Walker, S; Wilkison, WO; Kler, L (tháng 1 năm 2015). “Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes”. Diabetes Obes. Metab. 17 (1): 94–7. doi:10.1111/dom.12391. PMID 25223369.
↑ Sykes, AP; Kemp, GL; Dobbins, R; O'Connor-Semmes, R; Almond, SR; Wilkison, WO; Walker, S; Kler, L (tháng 1 năm 2015). “Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes”. Diabetes Obes Metab. 17 (1): 98–101. doi:10.1111/dom.12393. PMID 25238025.

Tài liệu tham khảo

WikiPedia: Remogliflozin etabonate http://www.chemspider.com/Chemical-Structure.80471... //pubmed.ncbi.nlm.nih.gov/21733056 //pubmed.ncbi.nlm.nih.gov/23011728 //pubmed.ncbi.nlm.nih.gov/25223369 //pubmed.ncbi.nlm.nih.gov/25238025 //www.ncbi.nlm.nih.gov/pmc/articles/PMC3476920 http://www.kegg.jp/entry/D10055 http://www.ama-assn.org/ama1/pub/upload/mm/365/rem... http://www.commonchemistry.org/ChemicalDetail.aspx... //doi.org/10.1111%2Fdom.12391